NextCure to Merge with Avere, Creating Once-Weekly Oral IL-23 Player
NXTC sits 87% above its 52-week low of $1.55 on elevated volume (2.2× avg).
Summary
NextCure is merging with private biotech Avere Therapeutics in an all-stock transaction to advance a once-weekly oral IL-23 therapy. The combined company will operate as Avere Therapeutics, with NextCure shareholders owning roughly 25% and Avere shareholders 75%. The deal is expected to close in Q4 2026. Concurrently, NextCure announced a $320 million private investment from an investor syndicate. This follows NextCure's going concern warning and cash runway into H1 2027, providing a path forward for its pipeline. NextCure's recent positive Phase 1 data for SIM0505 adds to the combined entity's oncology assets.
At the time of this announcement, NXTC was trading at $2.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.9M. The 52-week trading range was $1.55 to $15.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.